1
|
Fardella E, Zanirato G, Magni M, Caldarelli N, Chiappella A, Dodero A, Ljevar S, Orsucci L, Re A, Usai SV, Stefoni V, Castellino C, Rossi FG, Pinto A, Carniti C, Corradini P. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas. Br J Haematol 2024. [PMID: 38176400 DOI: 10.1111/bjh.19280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/14/2023] [Accepted: 12/19/2023] [Indexed: 01/06/2024]
Abstract
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis and, to date, there are no reliable predictive biomarkers of response. In this work we explored the prognostic impact of cell-free DNA (cfDNA) concentration in 75 newly diagnosed patients enrolled in a prospective multicenter study. Pre-treatment cfDNA was strongly associated with clinical risk factors and was identified as a superior predictor for shorter progression-free survival in multivariable analysis, outweighing canonical risk parameters. Furthermore, we identified a cfDNA value above which survival worsens. In conclusion, pre-treatment cfDNA concentration represents an easily usable predictive biomarker that is highly associated with survival of PTCL patients.
Collapse
Affiliation(s)
| | - G Zanirato
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Magni
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | - A Chiappella
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Dodero
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Ljevar
- Unit of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - L Orsucci
- Division of Hematology, Azienda Ospedaliera e Universitaria Città della Salute e della Scienza, Turin, Italy
| | - A Re
- Hematology Division, ASST Spedali Civili di Brescia, Brescia, Italy
| | - S V Usai
- Hematology Unit, Ospedale Oncologico Armando Businco, Cagliari, Italy
| | - V Stefoni
- Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy
| | - C Castellino
- Division of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
| | - F G Rossi
- Division of Hematology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - A Pinto
- Hematology-Oncology & Stem Cell Transplantation Unit, IRCCS Istituto Nazionale Tumori, Fondazione G. Pascale, Napoli, Italy
| | - C Carniti
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Corradini
- University of Milan, Milan, Italy
- Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
2
|
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. Ann Oncol 2024; 35:118-129. [PMID: 37922989 DOI: 10.1016/j.annonc.2023.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/11/2023] [Accepted: 10/03/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. PATIENTS AND METHODS Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). RESULTS Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). CONCLUSIONS Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
Collapse
Affiliation(s)
- M Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
| | - R Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Zanni
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - A Evangelista
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - S Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - A Tucci
- Department of Hematology, Spedali Civili, Brescia
| | - B Botto
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - S Bolis
- SC Ematologia ASST-Monza, Monza
| | - S Volpetti
- Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine
| | - V R Zilioli
- Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano
| | - B Puccini
- Department of Haematology, University of Florence, Firenze
| | - A Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza
| | - V Pavone
- A. O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce
| | - G Gaidano
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara
| | - P Corradini
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milano
| | - M Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna
| | - F Cavallo
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - G Milone
- Division of Hematology and Program for Hematopoietic Transplantation, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania
| | - C Ghiggi
- Hematology Division, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova
| | - A Pinto
- Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale", Naples
| | | | - A J M Ferreri
- Onco-Hematology Department, Fondazione Centro San Raffaele, Milano
| | - G Latte
- Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital, Nuoro
| | - C Patti
- Divisione di Oncoematologia, Azienda Villa Sofia - Cervello, Palermo
| | - F Re
- Department of Hematology, A.O.U. di Parma, Parma
| | - F Benedetti
- Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona
| | - S Luminari
- Department of Hematology, IRCCS Reggio Emilia, Reggio Emilia
| | - E Pennese
- Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara
| | - E Bossi
- SC Ematologia ASST-Monza, Monza
| | - C Boccomini
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - A Anastasia
- Department of Hematology, Spedali Civili, Brescia
| | - C Bottelli
- Department of Hematology, Spedali Civili, Brescia
| | - G Ciccone
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - U Vitolo
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| |
Collapse
|
3
|
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 2022; 7:100403. [PMID: 35272130 PMCID: PMC8795783 DOI: 10.1016/j.esmoop.2022.100403] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Revised: 01/13/2022] [Accepted: 01/18/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. METHODS This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND CONCLUSION The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
Collapse
Affiliation(s)
- C Buske
- Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
| | - M Dreyling
- Department of Medicine III at LMU Hospital, Munich, Germany
| | - A Alvarez-Larrán
- Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - J Apperley
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK
| | - L Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy
| | - C Besson
- Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; UVSQ, Inserm, CESP, Villejuif, France
| | - L Bullinger
- Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - P Corradini
- Hematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - M Giovanni Della Porta
- Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
| | - M Dimopoulos
- Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - S D'Sa
- UCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK
| | - H T Eich
- Department of Radiation Oncology, University of Muenster, Münster, Germany
| | - R Foà
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - P Ghia
- Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
| | - M G da Silva
- Department Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal
| | - J Gribben
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - R Hajek
- Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - C Harrison
- Clinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany
| | - B Kiesewetter
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
| | - J J Kiladjian
- Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France
| | - N Kröger
- Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - P Moreau
- Hematology Department, University Hospital Hotel-Dieu, Nantes, France
| | - J R Passweg
- Hematology Division, Basel University Hospital, Basel, Switzerland
| | - F Peyvandi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - D Rea
- University Medical Department of Hematology and Immunology, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France
| | - J-M Ribera
- Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
| | - T Robak
- Department of Hematology, Medical University of Lodz, Lodz, Poland
| | - J F San-Miguel
- Clínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain
| | - V Santini
- MDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy
| | - G Sanz
- Hematology Department, Hospital Univesitario y Politecnico La Fe, Valencia; CIBERONC, IS Carlos III, Madrid, Spain
| | - P Sonneveld
- Erasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands
| | - M von Lilienfeld-Toal
- Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany
| | - C Wendtner
- Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
| | - G Pentheroudakis
- Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland
| | - F Passamonti
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
| |
Collapse
|
4
|
Chiappella A, Guidetti A, Dodero A, Bramanti S, Zinzani P, Santoro A, Casadei B, Di Rocco A, Carrabba M, Chiusolo P, Martino M, Barbui AM, Tisi MC, Miceli R, Carniti C, Corradini P. FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY. Hematol Oncol 2021. [DOI: 10.1002/hon.187_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - A. Guidetti
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. Bramanti
- Humanitas Clinical and Research Center IRCCS Hematology Rozzano Italy
| | - P. Zinzani
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - A. Santoro
- Humanitas Clinical and Research Center IRCCS Hematology Rozzano Italy
| | - B. Casadei
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - A. Di Rocco
- 'Sapienza' University of Rome Department of Translational and Precision Medicine Roma Italy
| | - M. Carrabba
- San Raffaele Hospital IRCCS Hematology and Bone Marrow Transplantation Unit Milano Italy
| | - P. Chiusolo
- Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica del Sacro Cuore Department of Diagnostica per Immagini Radioterapia Oncologica ed Ematologia Hematology Section Department of Scienze Radiologiche ed Ematologiche Roma Italy
| | - M. Martino
- Grande Ospedale Metropolitano “Bianchi‐Melacrino‐Morelli” Stem Cell Transplant and Cellular Therapies Unit Reggio Calabria Italy
| | - A. M. Barbui
- Azienda Socio Sanitaria Territoriale (ASST), Ospedale Papa Giovanni XXIII Hematology Unit Bergamo Italy
| | - M. C. Tisi
- San Bortolo Hospital Cell Therapy and Hematology Vicenza Italy
| | - R. Miceli
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Unit of Clinical Epidemiology and Trial Organization Department of Applied Research and Technological Development Milano Italy
| | - C. Carniti
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
5
|
Pulsoni A, Tosti ME, Ferrero S, Luminari S, Dondi A, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJ, Rattotti S, Zilioli VR, Bernuzzi P, Bolis S, Musuraca G, Nassi L, Perrone T, Stelitano C, Anastasia A, Corradini P, Partesotti G, Re F, Cencini E, Mannarella C, Mannina D, Molinari AL, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Ciabatti E, Mantoan B, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pulsoni
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - M. E. Tosti
- Istituto Superiore di Sanità National Center for Global Health Roma Italy
| | - S. Ferrero
- Hematology Division University of Torino/AOU "Città della Salute e della Scienza di Torino" Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - S. Luminari
- Hematology Unit Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale ‐ IRCCS, University of Modena and Reggio Emilia Reggio Emilia Italy
| | - A. Dondi
- Fondazione Italiana Linfomi Onlus, (FIL) Modena Italy
| | - A. M. Liberati
- A.O. Santa Maria Terni, University of Perugia Perugia Italy
| | - N. Cenfra
- Hematology Unit, S. Maria Goretti Hospital AUSL Latina Latina Italy
| | - D. Renzi
- Hematology and Stem Cells Transplantation Unit IRCCS Istituto Nazionale dei Tumori Regina Elena Roma Italy
| | - M. Zanni
- Division of Hematology, SS. Antonio e Biagio Hospital Alessandria Italy
| | - C. Boccomini
- Hematology Department Città della Salute e della Scienza Torino Italy
| | - A. J. Ferreri
- Lymphoma Unit IRCCS San Raffaele Scientific Institute Department of Onco‐Haematology Milano Italy
| | - S. Rattotti
- Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy
| | - P. Bernuzzi
- Hematology Unit, Guglielmo da Saliceto Hospital Department of Onco‐Hematology Piacenza Italy
| | - S. Bolis
- Hematology Department ASST San Gerardo University Hospital Monza Italy
| | - G. Musuraca
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola (FC) Italy
| | - L. Nassi
- Division of Hematology University of Eastern Piedmont Department of Translational Medicine Novara Italy
| | - T. Perrone
- Unit of Hematology with Transplantation University of Bari, Dept. of Emergency and Organ Transplantation Bari Italy
| | - C. Stelitano
- Department of Haematology Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Anastasia
- Hematology, ASST Spedali Civili di Brescia Brescia Italy
| | - P. Corradini
- Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy
| | - G. Partesotti
- Onco‐Hematology Department Nuovo ospedale civile of Sassuolo Sassuolo Italy
| | - F. Re
- Hematology Clinic, A.O.U. di Parma Parma Italy
| | - E. Cencini
- Unit of Hematology Azienda Ospedaliera Universitaria Senese & University of Siena Siena Italy
| | - C. Mannarella
- Hematology Unit "Madonna delle Grazie" Hospital Matera Italy
| | - D. Mannina
- Department of Hematology Azienda Ospedaliera Papardo Messina Italy
| | | | - M. Tani
- Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
| | - G. Annechini
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - G. M. Assanto
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Grapulin
- Department of Radiotherapy Policlinico Umberto I, Sapienza University Roma Italy
| | - A. Guarini
- Hematology, Sapienza University Department of Molecular Medicine Roma Italy
| | - M. Cavalli
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. A. De Novi
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - E. Ciabatti
- Section of Hematology, University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - B. Mantoan
- Hematology Division University of Torino Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - I. Della Starza
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo University of Pavia, Department of Molecular Medicine Pavia Italy
| | - U. Ricardi
- Radiation Oncology, University of Turin Department of Oncology Torino Italy
| | - V. Gattei
- Clinical and Experimental Onco‐Hematology Unit CRO Aviano National Cancer Institute Aviano Italy
| | - S. Galimberti
- Section of Hematology University of Pisa, Department of Clinical and Experimental Medicine Pisa Italy
| | - M. Ladetto
- Hematology, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Università del Piemonte Orientale Alessandria Italy
| | - R. Foà
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - I. Del Giudice
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| |
Collapse
|
6
|
Chiappella A, Carniti C, Re A, Castellino C, Evangelista A, Ciancia R, Orsucci L, Pinto A, Usai SV, Arcari A, Ilariucci F, Rossi FG, Benedetti F, Flenghi L, Ghiggi C, Molinari AL, Stefoni V, Volpetti S, Zilioli VR, Ballerini F, Bruna R, Cavallo F, Musuraca G, Patti C, Re F, Tani M, Varettoni M, Zanni M, Dodero A, Pileri SA, Ciccone G, Corradini P. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.130_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - C. Carniti
- Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - A. Re
- ASST Spedali Civili di Brescia Hematology Division Brescia Italy
| | - C. Castellino
- Azienda Ospedaliera S. Croce e Carle Division of Hematology Cuneo Italy
| | - A. Evangelista
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - R. Ciancia
- Centro di Riferimento Oncologico (CRO) IRCCS Onco‐hematology and Stem Cell Transplantation and Cellular Therapies Aviano Italy
| | - L. Orsucci
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Torino Italy
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS Hematology‐Oncology & Stem Cell Transplantation Unit Napoli Italy
| | - S. V. Usai
- Ospedale Oncologico Armando Businco Hematology Cagliari Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Ilariucci
- Azienda USL‐IRCCS, Hematology Reggio Emilia Italy
| | - F. G. Rossi
- Fondazione IRCCS Cà Granda OM Policlinico Division of Hematology Milano Italy
| | - F. Benedetti
- Azienda Ospedaliera Universitaria di Verona Hematology and Stem Cell Transplantation Verona Italy
| | - L. Flenghi
- Azienda Ospedaliera di Perugia Hematology Perugia Italy
| | - C. Ghiggi
- IRCCS Ospedale Policlinico San Martino Hematology Genova Italy
| | | | - V. Stefoni
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - S. Volpetti
- Presidio Ospedaliero Universitario "Santa Maria della Misericordia” di Udine ASUFC Clinic of Hematology Udine Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - F. Ballerini
- IRCCS Ospedale Policlinico San Martino Clinic of Hematology Genova Italy
| | - R. Bruna
- Ospedale Maggiore Della Carità Division of Hematology Novara Italy
| | - F. Cavallo
- University of Torino Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Division of Hematology Meldola Italy
| | - C. Patti
- Azienda Villa Sofia Cervello Division of Onco‐Hematology Palermo Italy
| | - F. Re
- Azienda Ospedaliera‐Universitaria di Parma Hematology and CTMO Parma Italy
| | - M. Tani
- Ospedale Santa Maria delle Croci Hematology Unit Ravenna Italy
| | - M. Varettoni
- Fondazione IRCCS Policlinico San Matteo Division of Hematology Pavia Italy
| | - M. Zanni
- Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Division of Hematology Alessandria Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. A. Pileri
- European Institute of Oncology IRCCS Division of Haematopathology Milano Italy
| | - G. Ciccone
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
7
|
Dreger P, Ngoya M, Litovich C, Finel H, Herrera AF, Sauter C, Kharfan‐Dabaja M, Sureda A, Blaise D, Castagna L, Corradini P, Pastano R, Arat M, Boumendil A, Dietrich S, Schmitz N, Glass B, Montoto S, Hamadani M. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.53_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Dreger
- EBMT Lymphoma Working Party Paris France
| | - M. Ngoya
- EBMT Lymphoma Working Party Paris France
| | - C. Litovich
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - H. Finel
- EBMT Lymphoma Working Party Paris France
| | - A. F Herrera
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | - C. Sauter
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| | | | - A. Sureda
- EBMT Lymphoma Working Party Paris France
| | - D. Blaise
- EBMT Lymphoma Working Party Paris France
| | | | | | - R. Pastano
- EBMT Lymphoma Working Party Paris France
| | - M. Arat
- EBMT Lymphoma Working Party Paris France
| | | | | | - N. Schmitz
- EBMT Lymphoma Working Party Paris France
| | - B. Glass
- EBMT Lymphoma Working Party Paris France
| | - S. Montoto
- EBMT Lymphoma Working Party Paris France
| | - M. Hamadani
- CIBMTR Lymphoma Working Committee Milwaukee Wisconsin USA
| |
Collapse
|
8
|
Bannerji R, Yuen S, Phillips T, Arthur C, Isufi I, Marlton P, Seymour JF, Corradini P, Molinari A, Gritti G, Emmons R, Hirata J, Musick L, Saha S, Croft B, Flowers C. POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.23_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- R. Bannerji
- Rutgers Cancer Institute of New Jersey Section of Hematologic Malignancies New Brunswick New Jersey USA
| | - S. Yuen
- The Calvary Mater Newcastle Hospital Waratah Australia
| | - T. Phillips
- University of Michigan Medical School, Division of Hematology and Oncology Ann Arbor USA
| | - C. Arthur
- Royal North Shore Hospital Sydney Australia
| | - I. Isufi
- Yale University, Smilow Cancer Hospital Section of Hematology New Haven USA
| | - P. Marlton
- Princess Alexandra Hospital and University of Queensland Department of Haematology Brisbane Australia
| | - J. F. Seymour
- Peter MacCallum Cancer Centre & Royal Melbourne Hospital Department of Haematology Melbourne Australia
| | - P. Corradini
- University of Milan, Istituto Nazionale dei Tumori Medical Oncology and Hematology Department Milan Italy
| | - A. Molinari
- AUSL Romagna Ospedale degli Infirmi Dirigente Medico Ematologia Rimini Italy
| | - G. Gritti
- ASST Papa Giovanni XXIII UOC Ematologia Bergamo Italy
| | - R. Emmons
- James Graham Brown Cancer Center Louisville USA
| | - J. Hirata
- Genentech, Inc. Product Development Oncology South San Francisco USA
| | - L. Musick
- Genentech, Inc. Product Development Oncology South San Francisco USA
| | - S. Saha
- F. Hoffmann‐La Roche Ltd Product Development Biometrics Welwyn Garden City UK
| | - B. Croft
- Genentech, Inc. Product Development Oncology South San Francisco USA
| | - C. Flowers
- M.D. Anderson Cancer Center Department of Lymphoma/Myeloma Houston USA
| |
Collapse
|
9
|
Guidetti A, Dodero A, Argiroffi G, Verderio P, Lorenzoni A, Chiappella A, Carniti C, Seregni E, Pizzamiglio S, Alessi A, Corradini P. QUANTITATIVE METABOLIC PARAMETERS EVALUATION IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMAS TREATED WITH ANTI‐CD19 CAR T‐CELLS. Hematol Oncol 2021. [DOI: 10.1002/hon.189_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Guidetti
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| | - G. Argiroffi
- Fondazione IRCCS Istituto dei Tumori Nuclear Medicine Milano Italy
| | - P. Verderio
- Fondazione IRCCS Istituto Nazionale dei Tumori Unit of Bioinformatics and Biostatistics Milano Italy
| | - A. Lorenzoni
- Fondazione IRCCS Istituto dei Tumori Nuclear Medicine Milano Italy
| | - A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| | - C. Carniti
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| | - E. Seregni
- Fondazione IRCCS Istituto dei Tumori Nuclear Medicine Milano Italy
| | - s. Pizzamiglio
- Fondazione IRCCS Istituto Nazionale dei Tumori Unit of Bioinformatics and Biostatistics Milano Italy
| | - A. Alessi
- Fondazione IRCCS Istituto dei Tumori Nuclear Medicine Milano Italy
| | - P. Corradini
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| |
Collapse
|
10
|
Capra M, Beksac M, Richardson P, Unal A, Corradini P, Delimpasi S, Gulbas Z, Mikala G, Neylon A, Symeonidis A, Bringhen S, Moreau P, Velde H, Campana F, Guennec S, Spicka I. ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS. Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.10.440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Olivieri A, Mancini G, Olivieri J, Marinelli Busilacchi E, Cimminiello M, Pascale SP, Nuccorini R, Patriarca F, Corradini P, Bacigalupo A, Angelini S, Poloni A, Grillo G, Onida F, Martino M, Di Renzo N, Nagler A, Mordini N, Bruno B, Ciceri F, Bonifazi F. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplant 2020; 55:2077-2086. [PMID: 32332918 DOI: 10.1038/s41409-020-0902-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Revised: 03/19/2020] [Accepted: 04/03/2020] [Indexed: 11/10/2022]
Abstract
We conducted a phase I-II study to evaluate Nilotinib (NIL) safety and pharmacokinetics in 22 SR-cGVHD patients; we also evaluated ORR by using in parallel NIH criteria and an exploratory approach, combining objective improvement (OI) without failure criteria (GITMO criteria). Results: 22 patients were enrolled. After dose escalation up to 600 mg/day, MTD was not reached. Main toxicities were asthenia, headache, nausea, pruritus, cramps, and mild anemia. Mean and median plasma concentrations of NIL (C-NIL) were 817 (SD ± 450) and 773 ng/ml. ORR at 6 months, according to 2005 and 2014 NIH and GITMO criteria were 27.8%, 22.2%, and 55.6% respectively; close correspondence has been observed for ORR, according to 2014 NIH criteria, both assessed in a conventional way and assisted by dedicated software (CROSY). At 48 months OS was 75% while FFS, according to NIH and GITMO criteria, was 30 and 25%. In conclusion the safety profile of NIL and long-term outcome makes NIL an attractive option in SR-cGVHD. Exploratory GITMO criteria could represent an alternative tool for easy response evaluation in patients with prevalent skin and lung involvement, but require validation in a larger population; CROSY software showed excellent reliability in capturing ORR according to the 2014 NIH criteria.
Collapse
Affiliation(s)
- A Olivieri
- Unit of Hematology, AUO Ospedali Riuniti di Ancona, Ancona, Italy. .,Department of Clinical and Molecular Science, Università Politecnica delle Marche, Ancona, Italy.
| | - G Mancini
- Unit of Hematology, AUO Ospedali Riuniti di Ancona, Ancona, Italy
| | - J Olivieri
- Department of Hematology, Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Integrata, Udine, Italy
| | - E Marinelli Busilacchi
- Department of Clinical and Molecular Science, Università Politecnica delle Marche, Ancona, Italy
| | - M Cimminiello
- Regional Department of Hematology, U.O.C. of Hematology and Stem Cell Transplantation, Azienda Ospedaliera Regionale San Carlo, Potenza, Italy
| | - S P Pascale
- Regional Department of Hematology, U.O.C. of Hematology and Stem Cell Transplantation, Azienda Ospedaliera Regionale San Carlo, Potenza, Italy
| | - R Nuccorini
- Regional Department of Hematology, U.O.C. of Hematology and Stem Cell Transplantation, Azienda Ospedaliera Regionale San Carlo, Potenza, Italy
| | - F Patriarca
- Department of Hematology, Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Integrata, Udine, Italy
| | - P Corradini
- Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Bacigalupo
- Department of Hematology, Fondazione Policlinico Universitario Gemelli IRCCS, Universita' Cattolica del Sacro Cuore, Roma, Italy
| | - S Angelini
- U.O.C of Hematology, Ospedale C.G. Mazzoni, Ascoli Piceno, Italy
| | - A Poloni
- Unit of Hematology, AUO Ospedali Riuniti di Ancona, Ancona, Italy.,Department of Clinical and Molecular Science, Università Politecnica delle Marche, Ancona, Italy
| | - G Grillo
- Division of Hematology and Oncology, ASST Grande Ospedale Metropolitano Niguarda Milan, Milan, Italy
| | - F Onida
- BMT Center, Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - M Martino
- Stem Cell Transplantation Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
| | - N Di Renzo
- Haematology and BMT Unit, Ospedale Vito Fazzi, Lecce, Italy
| | - A Nagler
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Tel Aviv University, Tel Aviv, Israel
| | - N Mordini
- BMT Center, Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - B Bruno
- S.S.D. Allogenic Stem Cell Transplantation, Department of Oncology, Presidio Molinette, AOU Città della Salute e della Scienza di Torino, Torino, Italy
| | - F Ciceri
- IRCCS San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milano, Italy
| | - F Bonifazi
- Institute of Hematology, "Seragnoli" University Hospital S. Orsola-Malpighi, Bologna, Italy
| |
Collapse
|
12
|
Borreani C, Alfieri S, Farina L, Bianchi E, Corradini P. Fear of cancer recurrence in haematological cancer patients: exploring socio-demographic, psychological, existential and disease-related factors. Support Care Cancer 2020; 28:5973-5982. [PMID: 32285261 DOI: 10.1007/s00520-020-05434-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 03/27/2020] [Indexed: 01/02/2023]
Abstract
PURPOSE This study aims to explore the relation between the dimension of fear of cancer recurrence (FCR) in haematological cancer patients relapse-free for at least 2 years and socio-demographic, related to the disease, psychological and existential factors. METHODS A sample of 75 haematological cancer patients agreed to participate in the study through a self-reported online questionnaire (51.9% males). A total of 70.1% had a low recurrence risk. The questionnaire included socio-demographic (gender, age, civil status, level of education and number of children), related to the disease (diagnosis, therapeutic line and years since diagnosis), psychological (anxiety and depression), existential (purpose in life; PIL) factors and Fear of Cancer Recurrence Concerns Inventory (FCRI). Simple and multiple linear regressions were conducted for the analyses, and we performed some preliminary analysis on the reliability of the FCRI. FINDINGS A total of 53.3% of participants showed clinical levels of FCR on the severity dimension, which was higher than found in previous research in other cancer patients. The coping strategies, triggers, severity and psychological distress dimensions showed higher mean values. Women, patients with indolent non-Hodgkin lymphomas, years since diagnosis, anxiety and purpose in life are significantly related to one or more dimensions of FCRI. IMPLICATIONS It is important that the clinicians have at their disposal multiple possibilities to help patients cope with haematological cancer. If future research will confirm the results of this study, the negative correlation between FCR and PIL can suggest indications for planning interventions based on a salutogenic approach.
Collapse
Affiliation(s)
- C Borreani
- Clinical Psychology Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Via Giacomo Venezian 1, 20133, Milan, Italy
| | - S Alfieri
- Clinical Psychology Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Via Giacomo Venezian 1, 20133, Milan, Italy.
| | - L Farina
- Haematological Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Milan, Italy
| | - E Bianchi
- Clinical Psychology Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Via Giacomo Venezian 1, 20133, Milan, Italy
| | - P Corradini
- Haematological Unit, Fondazione IRCSS "Istituto Nazionale dei Tumori", Milan, Italy
| |
Collapse
|
13
|
Bachanova V, Westin J, Tam C, Borchmann P, Jaeger U, McGuirk J, Holte H, Waller E, Jaglowski S, Bishop M, Andreadis C, Foley S, Fleury I, Teshima T, Mielke S, Salles G, Ho P, Izutsu K, Maziarz R, Van Besien K, Kersten M, Wagner-Johnston N, Kato K, Corradini P, Han X, Agoulnik S, Chu J, Eldjerou L, Pacaud L, Schuster S. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.118_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- V. Bachanova
- Division of Hematology; Oncology and Transplantation, University of Minnesota; Minneapolis United States
| | - J. Westin
- Department of Lymphoma & Meyloma; M.D. Anderson Cancer Center; Houston United States
| | - C. Tam
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - P. Borchmann
- Department of Hematology/Oncology; University Hospital of Cologne; Cologne Germany
| | - U. Jaeger
- Department of Hematology/Hemostaseology; Medical University Vienna; Vienna Austria
| | - J. McGuirk
- Division of Hematologic Malignancies and Cellular Therapeutics; Kansas Hospital and Medical Center; Kansas City United States
| | - H. Holte
- Lymphoma Section; University of Oslo; Oslo Norway
| | - E. Waller
- Department of Stem Cell Transplantation and Immunology; Emory University School of Medicine; Atlanta United States
| | - S. Jaglowski
- Department of Internal Medicine; The Ohio State University; Columbus United States
| | - M. Bishop
- Section of Hematology/Oncology; University of Chicago; Chicago United States
| | - C. Andreadis
- Department of Hematology and Blood and Marrow Transplat; University of California San Francisco; San Francisco United States
| | - S.R. Foley
- Division of Clinical Pathology; McMaster University; Hamilton Canada
| | - I. Fleury
- Department of Hematology; Hôpital Maisonneuve-Rosemont; Montreal Canada
| | - T. Teshima
- Department of Hematology; Hokkaido University Hospital; Sapporo Japan
| | - S. Mielke
- Department of Internal Medicine; University Hospital Wuerzburg; Wuerzburg Germany
| | - G. Salles
- Hematology Department; Lyon-Sud Hospital Center; Pierre-Benite France
| | - P.J. Ho
- Department of Haematology; Royal Prince Alfred Hospital; Camperdown Australia
| | - K. Izutsu
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - R. Maziarz
- Department of Hematology and Oncology; Oregon Health and Science University; Portland United States
| | - K. Van Besien
- Department of Medical Oncology; Weill Cornell Medicine; New York United States
| | - M.J. Kersten
- Department of Hematology; Academic Medical Center; Amsterdam Netherlands
| | - N. Wagner-Johnston
- Department of Oncology and Hematologic Malignancies; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Baltimore United States
| | - K. Kato
- Hematology; Oncology & Cardiovascular Medicine, Kyushu University; Fukuoka Prefecture Japan
| | - P. Corradini
- Department of Oncology and Hemato-oncology; University of Milan; Milan Italy
| | - X. Han
- Biomarkers and Diagnostics Biometrics; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - S. Agoulnik
- Precision Medicine; Novartis Pharmaceuticals Corporation; Cambridge United States
| | - J. Chu
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - L. Eldjerou
- Global Cell & Gene Medical Affairs; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - L. Pacaud
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - S. Schuster
- Division of Hematology Oncology; University of Pennsylvania; Philadelphia United States
| |
Collapse
|
14
|
Lopez-Parra M, Bellei M, Rambaldi A, Novelli S, Panizo C, Martelli M, Dhouly I, Bastos M, Gutierrez A, Sancho J, Ramirez M, Moraleda J, Carrillo Cruz E, Jimenez Ubieto A, Jarque I, Vittolo U, de las Heras N, Arranz R, Lopez-Jimenez J, Montalbán C, Pascual M, Corradini P, Bobillo S, Estefania G, Spina M, Rossi G, Manni M, Federico M, Caballero D, Martín A. AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.63_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- M. Lopez-Parra
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| | - M. Bellei
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena; Modena Italy
| | - A. Rambaldi
- Hematology and bone marrow transplant Unit; University of Milan; Milan Italy
| | - S. Novelli
- Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - C. Panizo
- Hematology; Clínica Universidad de Navarra; Pamplona Spain
| | - M. Martelli
- Hematology; Sapienza, University of Rome; Rome Italy
| | - I. Dhouly
- Hematology; Hospital Clinic de Barcelona; Barcelona Spain
| | - M. Bastos
- Hematology; Hospital Gregorio Marañón; Madrid Spain
| | - A. Gutierrez
- Hematology; Hospital Son de Espases; Palma Spain
| | - J. Sancho
- Hematology; Hospital Germans Trias i Pujol/ ICO-IJC; Barcelona Spain
| | - M. Ramirez
- Hematology; Hospital de Jerez de la Frontera; Jerez de la Frontera Spain
| | - J. Moraleda
- Hematology; Hospital Vírgen de la Arrixaca; Murcia Spain
| | | | | | - I. Jarque
- Hematology; Hospital Universitario y Politécnico La Fe; Valencia Spain
| | - U. Vittolo
- Dipartimento di Oncologia e Ematologia; Città della Salute e della Scienza di Torino; Turin Italy
| | - N. de las Heras
- Hematology; Complejo Asistencial Universitario de León; León Spain
| | - R. Arranz
- Hematology; Hospital La Princesa; Madrid Spain
| | | | - C. Montalbán
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - M. Pascual
- Hematology; Hospital Carlos Haya; Málaga Spain
| | | | - S. Bobillo
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | | | - M. Spina
- Division of Medical Oncology; National Cancer Institute; Aviano Italy
| | - G. Rossi
- Hematology; Spedali Civili; Brescia Italy
| | - M. Manni
- Diagnostic; Clinic and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Hematology; Università degli Studi di Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| | - A. Martín
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| |
Collapse
|
15
|
Federico M, Mannina D, Versari A, Ferrero S, Marcheselli L, Boccomini C, Dondi A, Tucci A, Guerra L, Galimberti S, Cavallo F, Olivieri J, Corradini P, Arcaini L, Chauvie S, Del Giudice I, Rusconi C, Pinto A, Molinari A, Pulsoni A, Merli M, Kovalchuk S, Nassi L, Bolis S, Gattei V, Manni M, Pileri S, Brugiatelli M, Luminari S. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Federico
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - A. Versari
- Nuclear Medicine Unit; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - S. Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Division of Hematology; University of Torino; Torino Italy
| | - L. Marcheselli
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - C. Boccomini
- SC Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Dondi
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - A. Tucci
- SC Ematologia; ASST-Spedali Civili; Brescia Italy
| | - L. Guerra
- Nuclear Medicine Unit; San Gerardo Hospital; Monza Italy
| | - S. Galimberti
- Division of Hematology, Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - J. Olivieri
- Clinica Ematologica; Centro Trapianti e Terapie Cellulari “C. Melzi”, DAME, ASUI; Udine Italy
| | - P. Corradini
- Department of Oncology and Hematology; Fondazione Istituto Nazionale dei Tumori Milano University of Milano; Milano Italy
| | - L. Arcaini
- Department of Molecular Medicine; University of Pavia, Division of Hematology, Fondazione IRCCS Policlinico S. Matteo; Pavia Italy
| | - S. Chauvie
- Medical Physics Unit; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - I. Del Giudice
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - C. Rusconi
- Division of Hematology; ASST Grande ospedale Metropolitano Niguarda; Milano Italy
| | - A. Pinto
- Department of Hematology and Developmental Therapeutics; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’ IRCCS; Napoli Italy
| | - A. Molinari
- UO Ematologia; OC Rimini AUSL Romagna; Rimini Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - M. Merli
- Hematology; University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria; Varese Italy
| | - S. Kovalchuk
- Ematologia; Università degli Studi di Firenze; Firenze Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - S. Bolis
- Hematolgy Unit; ASST-Monza; Monza Italy
| | - V. Gattei
- Clinical and Experimental Onco-Haematology Unit; Centro di Riferimento Oncologico, IRCCS; Aviano Italy
| | - M. Manni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - S. Pileri
- Divisione di Diagnosi Ematopatologica; Istituto Europeo di Oncologia; Milano Italy
| | - M. Brugiatelli
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - S. Luminari
- S.C. Ematologia; Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia Italy
| |
Collapse
|
16
|
Jaeger U, Tam C, Borchmann P, McGuirk J, Holte H, Waller E, Jaglowski S, Andreadis C, Foley S, Fleury I, Westin J, Teshima T, Mielke S, Salles G, Ho P, Izutsu K, Schuster S, Bachanova V, Maziarz R, Van Besien K, Kersten M, Wagner-Johnston N, Kato K, Corradini P, Tiwari R, Forcina A, Pacaud L, Bishop M. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.189_2631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- U. Jaeger
- Hematology and Hemostaseology; and Comprehensive Cancer Center, Medical University of Vienna; Vienna Austria
| | - C. Tam
- Department of Hematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - P. Borchmann
- Department of Hematology/Oncology; University Hospital of Cologne; Cologne Germany
| | - J. McGuirk
- Division of Hematologic Malignancies and Cellular Therapeutics; Kansas Hospital and Medical Center; Kansas City United States
| | - H. Holte
- Lymphoma Section; University of Oslo, Oslo
| | - E. Waller
- Hematology and Medical Oncology; Medicine and Pathology, Emory University School of Medicine; Atlanta United States
| | - S. Jaglowski
- Department of Hematology; Ohio State University, Columbus
| | - C. Andreadis
- Department of Hematology and Blood and Marrow Transplant; University of California San Francisco; San Francisco United States
| | - S.R. Foley
- Division of Clinical Pathology; McMaster University; Hamilton Canada
| | - I. Fleury
- Department of Hematology; Hôpital Maisonneuve-Rosemont; Montreal Canada
| | - J. Westin
- Department of Lymphoma & Meyloma; MD Anderson Cancer Center; Houston United States
| | - T. Teshima
- Department of Hematology; Hokkaido University Hospital; Sapporo Japan
| | - S. Mielke
- Department of Internal Medicine; University Hospital Wuerzburg; Wuerzburg Germany
| | - G. Salles
- Department of Hematology/Oncology; Hospital Center Lyon-Sud; Pierre-Benite France
| | - P.J. Ho
- Department of Haematology; Royal Prince Alfred Hospital; Camperdown Australia
| | - K. Izutsu
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - S. Schuster
- Division of Hematology Oncology; University of Pennsylvania; Philadelphia United States
| | - V. Bachanova
- Division of Hematology; Oncology and Transplantation, University of Minnesota; Minneapolis United States
| | - R. Maziarz
- Department of Hematology; Oregon Health and Science University; Portland United States
| | - K. Van Besien
- Department of Medical Oncology; Weill Cornell Medicine; New York United States
| | - M.J. Kersten
- Department of Hematology; Academic Medical Center; Amsterdam Netherlands
| | - N. Wagner-Johnston
- Department of Hematology/Oncology; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Baltimore United States
| | - K. Kato
- Department of Haematology; Kyushu University Hospital; Fukuoka Prefecture Japan
| | - P. Corradini
- Department of Oncology and Hemato-oncology; University of Milan; Milan Italy
| | - R. Tiwari
- Global Medical Affaris; Novartis Pharmaceuticals Corporation; Hyderabad India
| | - A. Forcina
- Novartis Oncology; Novartis Pharma AG; Basel Switzerland
| | - L. Pacaud
- Novartis Oncology; Novartis Pharmaceuticals Corporation; East Hanover United States
| | - M. Bishop
- Section of Hematology/Oncology; University of Chicago; Chicago United States
| |
Collapse
|
17
|
Chiappella A, Carniti C, Evangelista A, Re A, Cabras M, Stefoni V, Castellino C, Congiu A, Pinto A, Zanni M, Rusconi C, Molinari A, Ciancia R, Baldini L, Nassi L, Re F, Tani M, Ilariucci F, Cavallo F, Santoro A, Volpetti S, Dodero A, Pileri S, Ciccone G, Corradini P. PHASE II FIL-PTCL13 STUDY OF ROMIDEPSIN-CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.3_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Chiappella
- Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - C. Carniti
- Ematologia; Università degli Studi di Milano; Milano Italy
| | - A. Evangelista
- SSD Epidemiologia Clinica e Valutativa; Clinical Trial Center, AOU Città della Salute e della Scienza di Torino e CPO Piemonte; Torino Italy
| | - A. Re
- Ematologia; ASTT Spedali Civili di Brescia; Brescia Italy
| | - M.G. Cabras
- Ematologia; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - V. Stefoni
- Ematologia; Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli"; Bologna Italy
| | - C. Castellino
- Ematologia e Trapianto di Midollo Osseo; AO Santa Croce e Carle; Cuneo Italy
| | - A.G. Congiu
- Ematologia; Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia; Genova Italy
| | - A. Pinto
- Ematologia Oncologica; Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale; Napoli Italy
| | - M. Zanni
- Ematologia; AO SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| | - C. Rusconi
- Ematologia; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | | | - R. Ciancia
- Oncoematologia; trapianti emopoietici e terapie cellulari, Centro di Riferimento Oncologico CRO, IRCCS; Aviano Italy
| | - L. Baldini
- Ematologia; Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda; Milano Italy
| | - L. Nassi
- Ematologia; AOU Maggiore della Carità di Novara; Novara Italy
| | - F. Re
- Ematologia e CTMO; AOU Ospedale Maggiore di Parma; Parma Italy
| | - M. Tani
- Ematologia; Ospedale Santa Maria delle Croci; Ravenna Italy
| | - F. Ilariucci
- Ematologia; Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS; Reggio Emilia Italy
| | - F. Cavallo
- Ematologia; Università degli Studi - AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Santoro
- Ematologia; Istituto Clinico Humanitas; Rozzano Italy
| | - S. Volpetti
- Ematologia; ASUI Santa Maria della Misericordia; Udine Italy
| | - A. Dodero
- Ematologia; Fondazione IRCCS Istituto Nazionale dei Tumori; Milano Italy
| | - S.A. Pileri
- Emopatologia; Istituto Europeo Oncologico IRCCS; Milano Italy
| | - G. Ciccone
- SSD Epidemiologia Clinica e Valutativa; Clinical Trial Center, AOU Città della Salute e della Scienza di Torino e CPO Piemonte; Torino Italy
| | - P. Corradini
- Ematologia; Fondazione IRCCS Istituto Nazionale dei Tumori - Università degli Studi di Milano; Milano Italy
| |
Collapse
|
18
|
Carniti C, Biancon G, Banfi S, Vella C, Magni M, Pennisi M, Anna D, Guidetti A, Corradini P. PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B-CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000563532.69483.ec] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
19
|
Robinson S, Boumendil A, Finel H, Khvedelidze I, Kanfer E, Peggs K, Fuesrt S, Ram R, Marjit E, Vandenberghe E, Afanasyev B, Wulf G, Maertens J, Tsolukani A, Schapp N, Beelen D, Chalandon Y, Gurman G, Finke J, Bron D, Tischer J, Corradini P, Caballero D, Potter V, Kroger N, Burney C, Schmitz N, Sureda A, Dreger P, Montoto S. DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.125_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Robinson
- Haematology; University Hospital Bristol; Bristol United Kingdom
| | | | | | | | - E. Kanfer
- Haematology; Hammersmith Hospital; London United Kingdom
| | - K. Peggs
- Haematology; University College London Hospital; London United Kingdom
| | - S. Fuesrt
- Haematology; Paoli Calmettes; Marseille France
| | - R. Ram
- Haematology; Sourasky; Tel Aviv Israel
| | - E. Marjit
- Haematology; Leiden University; Leiden Netherlands
| | | | - B. Afanasyev
- Haematology; Pavlov Medical University; St Petersberg Russian Federation
| | - G. Wulf
- Haematology; University Hospital; Goettingen Germany
| | - J. Maertens
- Haematology; University Hospital; Leuven Netherlands
| | - A. Tsolukani
- Haematology; City Hospital; Nottingham United Kingdom
| | - N. Schapp
- Haematology; St Radboud Hospital; Nijmegen Netherlands
| | - D. Beelen
- Haematology; University Hospital; Essen Germany
| | - Y. Chalandon
- Haematology; University Hospital; Geneva Switzerland
| | - G. Gurman
- Haematology; Ankara University; Ankara Turkey
| | - J. Finke
- Haematology; University of Freiburg; Freiburg Germany
| | - D. Bron
- Haematology; Institute Jules Bordet; Brussels Belgium
| | - J. Tischer
- Haematology; Med Klinik Klinikum Grosshaderm; Munich Germany
| | - P. Corradini
- Haematology; Istituto Nazionale dei Tumori; Milan Italy
| | | | - V. Potter
- Haematology; Kings College hospital; London United Kingdom
| | - N. Kroger
- Haematology; University Hospital Eppendorf; Hamburg Germany
| | - C. Burney
- Haematology; University Hospital Bristol; Bristol United Kingdom
| | - N. Schmitz
- Haematology; University Hospital; Muenster Germany
| | - A. Sureda
- Haematology; Oncology Institute; Barcelona Spain
| | - P. Dreger
- Haematology; University of Heidelberg; Heidleberg Germany
| | - S. Montoto
- Haematology; St Bartholomew's Hospital; London United Kingdom
| |
Collapse
|
20
|
Stefoni V, Broccoli A, Botto B, Corradini P, Pinto A, Re A, Vitolo U, Fanti S, Argnani L, Zinzani P. FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS. Hematol Oncol 2019. [DOI: 10.1002/hon.105_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- V. Stefoni
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - A. Broccoli
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - B. Botto
- Hematology; Department of Oncology, University Hospital Città della Salute e della Scienza; Turin Italy
| | - P. Corradini
- IRCCS Istituto Nazionale dei Tumori; University of Milano; Milan Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale; Naples Italy
| | - A. Re
- Hematology; Azienda socio-sanitaria territoriale, Ospedali Civili di Brescia; Brescia Italy
| | - U. Vitolo
- Hematology; Department of Oncology, University Hospital Città della Salute e della Scienza; Turin Italy
| | - S. Fanti
- Nuclear Medicine; Medicina Nucleare Metropolitana, Sant'Orsola-Malpighi Hospital, University of Bologna; Bologna Italy
| | - L. Argnani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
21
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
22
|
Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio MC, Matteucci P, Carniti C, Facchetti F, Rossi G, Corradini P. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia 2019; 33:1047-1051. [PMID: 30631117 PMCID: PMC6756077 DOI: 10.1038/s41375-018-0320-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 10/05/2018] [Accepted: 11/06/2018] [Indexed: 01/15/2023]
Affiliation(s)
- A Dodero
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Guidetti
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. .,Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
| | - A Tucci
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - F Barretta
- Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Novo
- Department of Hematology, Azienda Ospedaliero Universitaria Citta' della Salute e della Scienza di Torino, Torino, Italy
| | - L Devizzi
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Re
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - A Passi
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - A Pellegrinelli
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - G Pruneri
- Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.,Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - R Miceli
- Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - A Testi
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Pennisi
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M C Di Chio
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - P Matteucci
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - C Carniti
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - F Facchetti
- Department of Pathology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - G Rossi
- Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
| | - P Corradini
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.,Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy
| |
Collapse
|
23
|
Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Ann Hematol 2018; 97:1301-1315. [PMID: 29802458 DOI: 10.1007/s00277-018-3366-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2018] [Accepted: 05/06/2018] [Indexed: 12/19/2022]
Abstract
The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10-15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40-50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.
Collapse
Affiliation(s)
- A M Carella
- Division of Hematology and BMT Unit, Ospedale Policlinico San Martino, Genoa, Italy.
| | - P Corradini
- Division of Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Mussetti
- Division of Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - U Ricardi
- Department of Oncology, Università di Torino, Turin, Italy
| | - U Vitolo
- AOU Citta' della Salute e della Scienza, Turin, Italy
| | - S Viviani
- Division of Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
24
|
Maura F, Petljak M, Lionetti M, Cifola I, Liang W, Pinatel E, Alexandrov LB, Fullam A, Martincorena I, Dawson KJ, Angelopoulos N, Samur MK, Szalat R, Zamora J, Tarpey P, Davies H, Corradini P, Anderson KC, Minvielle S, Neri A, Avet-Loiseau H, Keats J, Campbell PJ, Munshi NC, Bolli N. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia 2018; 32:1044-1048. [PMID: 29209044 PMCID: PMC5886048 DOI: 10.1038/leu.2017.345] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- F Maura
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - M Petljak
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - M Lionetti
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Hematology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - I Cifola
- Institute for Biomedical Technologies, National Research Council, Milan, Italy
| | - W Liang
- Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - E Pinatel
- Institute for Biomedical Technologies, National Research Council, Milan, Italy
| | - L B Alexandrov
- Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
| | - A Fullam
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - I Martincorena
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - K J Dawson
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - N Angelopoulos
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - M K Samur
- Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - R Szalat
- Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - J Zamora
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - P Tarpey
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - H Davies
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - P Corradini
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - K C Anderson
- Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S Minvielle
- CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France and CHU de Nantes, Nantes, France
| | - A Neri
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Hematology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - H Avet-Loiseau
- Genomics of Myeloma Laboratory, L’Institut Universitaire du Cancer Oncopole, Toulouse, France
| | - J Keats
- Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - P J Campbell
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - N C Munshi
- Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Boston Veterans Administration Healthcare System, West Roxbury, MA, USA
| | - N Bolli
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
- Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
25
|
Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O’Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson K, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 2017. [DOI: 10.1038/leu.2017.344] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
26
|
Guidetti A, Mazzocchi A, Miceli R, Paterno' E, Taverna F, Spina F, Crippa F, Farina L, Corradini P, Gianni AM, Viviani S. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leuk Res 2017; 62:91-97. [PMID: 28992524 DOI: 10.1016/j.leukres.2017.09.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Revised: 09/01/2017] [Accepted: 09/25/2017] [Indexed: 01/23/2023]
Abstract
BACKGROUND Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. METHODS Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. FINDINGS 101 patients out of 116 had baseline TARC above 800pg/ml (median value 27515pg/ml (IQR, 11001-68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556pg/ml (IQR, 378-977pg/ml). TARC-1 values below 800pg/ml were associated with success of therapy (p=0.0003) and PET-2 negativity (p=0.001). TARC-1≤800pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1% vs 55.6%; p<0.0001) and in both subgroups of advanced (p=0.003) and early stage patients (p=0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p=0.0035). INTERPRETATION Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.
Collapse
Affiliation(s)
- A Guidetti
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Onco-Hematology, University of Milano, Milan, Italy
| | - A Mazzocchi
- Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - R Miceli
- Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Paterno'
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F Taverna
- Immunohematology and Transfusion Medicine Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F Spina
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F Crippa
- Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L Farina
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P Corradini
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Onco-Hematology, University of Milano, Milan, Italy
| | - A M Gianni
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Viviani
- Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|
27
|
Pellegrini C, Pulsoni A, Rigacci L, Patti C, Gini G, Tani M, Rusconi C, Romano A, Vanazzi A, Hohaus S, Mazza P, Molica S, Corradini P, Gaudio F, Ronconi F, Pinto A, Pavone V, Volpetti S, Visentin A, Bonfichi M, Schiavotto C, Spina M, Carella A, Argnani L, Zinzani P. REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Pellegrini
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - A. Pulsoni
- Hematology, Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L. Rigacci
- Hematology Department; University and Hospital Careggi; Florence Italy
| | - C. Patti
- Hematology; Azienda Ospedali Riuniti Villa Sofia Cervello; Palermo Italy
| | - G. Gini
- Hematology; Ospedali Riuniti; Ancona Italy
| | - M. Tani
- Hematology; Santa Maria delle Croci Hospital; Ravenna Italy
| | - C. Rusconi
- Division of Hematology Niguarda Cancer Center; Niguarda Hospital; Milan Italy
| | - A. Romano
- Hematology, Azienda Policlinico-OVE; University of Catania; Catania Italy
| | - A. Vanazzi
- Division of Clinical Haemato-Oncology; IEO; Milan Italy
| | - S. Hohaus
- Institute of Hematology; Catholic Unicversityof the Sacred Heart; Rome Italy
| | - P. Mazza
- Department of Hematology-Oncology; Ospedale Moscati; Taranto Italy
| | - S. Molica
- Hematology; Azienda Ospedaliera Pugliese-Ciaccio; Catanzaro Italy
| | - P. Corradini
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - F. Gaudio
- Hematology; Policlinico di Bari; Bari Italy
| | - F. Ronconi
- Division of Hematology and Stem Cell Transplantation Unit; Cardarelli Hospital; Naples Italy
| | - A. Pinto
- Hematology-Oncology and Stem Cell Transplantation Unit; National Cancer Institute, Fondazione Pascale, IRCCS; Naples Italy
| | - V. Pavone
- Hematology; Ospedale G. Panico; Lecce Italy
| | - S. Volpetti
- Hematology; Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padova Italy
| | - M. Bonfichi
- Hematology; IRCCS Policlinico San Matteo; Pavia Italy
| | | | - M. Spina
- Division of Medical Oncology A; National Cancer Institute; Aviano Italy
| | - A. Carella
- Division of Hematology 1; IRCCS A.O.U. San Martino IST; Genoa Italy
| | - L. Argnani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | - P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| |
Collapse
|
28
|
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs K, Afanasyev B, Diez-Martin J, Corradini P, Socié G, Robinson S, Gutiérrez-García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, Ghesquières H, Montoto S, Dreger P, Sureda A. BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_71] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Bazarbachi
- Department of internal medicine; American University of Beirut; Beirut Lebanon
| | - A. Boumendil
- EBMT LWP Paris Office; Hôpital Saint-Antoine; Paris France
| | - H. Finel
- EBMT LWP Paris Office; Hôpital Saint-Antoine; Paris France
| | - M. Mohty
- Service d'Hématologie et Thérapie Cellulaire; Hôpital Saint Antoine; Paris France
| | - L. Castagna
- Department of Hematology; Istituto Clinico Humanitas; Milan Italy
| | - D. Blaise
- Department of internal medicine; Institut Paoli Calmettes; Marseille France
| | - K. Peggs
- Department of internal medicine; University College London Hospital; London UK
| | - B. Afanasyev
- Department of internal medicine; First State Pavlov Medical University of St. Petersburg; St. Petersburg Russian Federation
| | - J. Diez-Martin
- Department of internal medicine; Hospital Gregorio Marañón; Madrid Spain
| | - P. Corradini
- IRCCS Istituto Nazionale dei Tumori; University of Milano; Milan Italy
| | - G. Socié
- Department of internal medicine; Hopital St. Louis; Paris France
| | - S. Robinson
- Department of internal medicine; University Hospital Bristol; Bristol UK
| | | | - F. Bonifazi
- S.Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | | | - Z. Gülbas
- Department of internal medicine; Anadolu Medical Center Hospital; Kocaeli Turkey
| | - A. Bloor
- Department of internal medicine; Christie NHS Trust Hospital; Manchester UK
| | - J. Delage
- Department of internal medicine; CHU Lapeyronie; Montpellier France
| | - A. Esquirol
- Department of internal medicine; Hospital Santa Creu i Sant Pau; Barcelona Spain
| | - R. Malladi
- Department of internal medicine; Queen Elizabeth Hospital; Birmingham UK
| | - C. Scheid
- Department of internal medicine; University of Cologne; Cologne Germany
| | - H. Ghesquières
- Department of internal medicine; Centre Hospitalier Lyon Sud; Lyon France
| | - S. Montoto
- Department of Haemato-oncology; St Bartholomew's Hospital; London UK
| | - P. Dreger
- Dept Medicine V; University of Heidelberg; Heidelberg Germany
| | - A. Sureda
- Department of Haematology; Institut Catala d'Oncologia, Hospital Duran I Reynals; Barcelona Spain
| |
Collapse
|
29
|
Chiappella A, Carniti C, Ceccarelli M, Cabras M, Re A, Salvi F, Santoro A, Stefoni V, Pileri S, Ciccone G, Corradini P. FIL-PTCL13: PHASE IB/II STUDY OF ROMIDEPSIN/CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Chiappella
- Hematology; AOU Città della Salute e della Scienza, On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - C. Carniti
- Division of Hematology and Bone Marrow Transplant, Fondazione IRCCS Istituto Nazionale dei Tumori; Department of Oncology and Hemato-Oncology; University of Milan, On behalf of Fondazione Italiana Linfomi (FIL); Milan Italy
| | - M. Ceccarelli
- Unit of Clinical Epidemiology, CPO; AOU Città della Salute e della Scienza di Torino, On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M.G. Cabras
- Hematology, Ospedale “A. Businco” Cagliari; Haematology & Transplant Centre “Wilma Deplano”, On behalf of Fondazione Italiana Linfomi (FIL); Cagliari Italy
| | - A. Re
- Hematology, Azienda Ospedaliera Spedali Civili di Brescia; On behalf of Fondazione Italiana Linfomi (FIL); Brescia Italy
| | - F. Salvi
- Hematology, Azienda Ospedaliera Nazionale SS.Antonio e Biagio e C. Arrigo; On behalf of Fondazione Italiana Linfomi (FIL); Alessandria Italy
| | - A. Santoro
- Hematology, Istituto Clinico Humanitas and IRCCS; On behalf of Fondazione Italiana Linfomi (FIL); Rozzano Italy
| | - V. Stefoni
- Hematology, Istituto L e A Seragnoli, Policlinico S. Orsola-Malpighi; On behalf of Fondazione Italiana Linfomi (FIL); Bologna Italy
| | - S. Pileri
- Institute of Hematology "L. e A. Seràgnoli", Universita degli Studi di Bologna and Haematopathology Unit; Istituto Europeo di Oncologia, On behalf of Fondazione Italiana Linfomi (FIL); Milan Italy
| | - G. Ciccone
- Unit of Clinical Epidemiology, CPO; AOU Città della Salute e della Scienza di Torino, On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - P. Corradini
- Division of Hematology and Bone Marrow Transplant, Fondazione IRCCS Istituto Nazionale dei Tumori; Department of Oncology and Hemato-Oncology; University of Milan, On behalf of Fondazione Italiana Linfomi (FIL); Milan Italy
| |
Collapse
|
30
|
Viviani S, Soldarini M, Cieri N, Arendar I, Materazzo C, Busia A, Matteucci P, Di Russo A, Corradini P. Second malignancies and cardiovascular diseases in long-term Hodgkin lymphoma survivors: The Istituto Nazionale Tumori of Milan (INT) experience. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Viviani
- Hematology and Pediatric Onco-Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - M. Soldarini
- Hematology and Pediatric Onco-Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - N. Cieri
- Hematology and Pediatric Onco-Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - I. Arendar
- 2Division of Cardiology and Pneumology; Fondazione IRCCS Istituto Tumori dei Tumori; Milan Italy
| | - C. Materazzo
- 2Division of Cardiology and Pneumology; Fondazione IRCCS Istituto Tumori dei Tumori; Milan Italy
| | - A. Busia
- 2Division of Cardiology and Pneumology; Fondazione IRCCS Istituto Tumori dei Tumori; Milan Italy
| | - P. Matteucci
- Hematology and Pediatric Onco-Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - A. Di Russo
- Radiotherapy; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - P. Corradini
- Hematology and Pediatric Onco-Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| |
Collapse
|
31
|
Spina F, Radice T, Dalto S, De Philippis C, Montefusco V, Dodero A, Farina L, Mussetti A, Soldarini M, Di Chio M, Viviani S, Corradini P. ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- F. Spina
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - T. Radice
- Chair of Hematology; University of Milan; Milan Italy
| | - S. Dalto
- Chair of Hematology; University of Milan; Milan Italy
| | | | - V. Montefusco
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - A. Dodero
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - L. Farina
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - A. Mussetti
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - M. Soldarini
- Chair of Hematology; University of Milan; Milan Italy
| | - M. Di Chio
- Chair of Hematology; University of Milan; Milan Italy
| | - S. Viviani
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - P. Corradini
- Chair of Hematology; University of Milan; Milan Italy
| |
Collapse
|
32
|
Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2016; 27:2251-2257. [DOI: 10.1093/annonc/mdw421] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 08/16/2016] [Accepted: 08/29/2016] [Indexed: 11/14/2022] Open
|
33
|
d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 Suppl 5:v108-15. [PMID: 26314772 DOI: 10.1093/annonc/mdv201] [Citation(s) in RCA: 140] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Affiliation(s)
- F d'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - P Gaulard
- Department of Pathology, Hôpital Henri Mondor, Créteil, France
| | - L Trümper
- Department of Hematology and Oncology, Georg August University, Göttingen, Germany
| | - P Corradini
- Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy
| | - W-S Kim
- Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Seoul, Korea
| | - L Specht
- Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | | | - M Ladetto
- Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|
34
|
Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant 2015; 50:505-10. [DOI: 10.1038/bmt.2014.310] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Revised: 11/27/2014] [Accepted: 12/02/2014] [Indexed: 11/09/2022]
|
35
|
Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S, Pimpinelli N, Rossi G, Zinzani P, Tura S. SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Ann Oncol 2014; 25:2339-2350. [DOI: 10.1093/annonc/mdu152] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
36
|
|
37
|
|
38
|
|
39
|
Longoni P, Milanesi M, Di Nicola M, Devizzi L, Carrabba M, Arienti F, Ravagnani F, Tarella C, Montefusco V, Gianni A, Corradini P, Magni M. Successful second autologous engraftment after long duration storage of hematopoietic stem cells. Bone Marrow Transplant 2013; 48:1480-1. [PMID: 23708707 DOI: 10.1038/bmt.2013.81] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P Longoni
- Cryopreservation Laboratory, Fondazione IRCCS, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Lenti S, Nuzzi G, Urselli A, Corradini P, Bagnardi R, Santoro L, Benci S, Meola S. The EDAPA Project (Education of self-measurement of blood pressure) in Grottaglie. Ital J Med 2013. [DOI: 10.4081/itjm.2008.1.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
AIM OF THE STUDY The EDAPA Project (Education of self-measurement of blood pressure) was conceived to train hypertensive patients in self blood pressure monitoring (SBPM) and to survey their feedback, including patient’ assessment, by recording their related cardiovascular diseases (CVD risks factors) and lifestyle habits. METHODS The project was conducted during the year 2006. Initially we met Grottaglie’s citizens and illustrated to participants the importance of SBPM at home in the overall management of hypertension, that might lead to a better control of BP and cardiovascular outcomes. After explaining the correct technique for SBPM, we distributed semiautomatic devices (OMRON M6) and asked the participants to fill in the Hypertension Questionnaire Form and to record their own blood pressure values in a diary. RESULTS Among almost 3,000 citizens interviewed, 370 (198 M, 172 F; mean age: 60 years) agreed to take part in our study. They were hypertensive for almost 10 years, but waited 3 years before beginning therapy. They measured BP 4 times a month and, in the same sitting, 66% of them carried out only 1 measurement, 29% of them 2 measurements and only 2.5% carried out 3 measurements. Taking as reference BP value of 135/85 mmHg, we registered 28% of the population as normotensive and the remaining 72% as hypertensive. Among the hypertensives, 30% showed a good control, 55% showed a bad one and the remaining 15% was not aware of being hypertensive. Adding non-treated hypertensives to those treated but not controlled, we noticed that 70% of the participants was not properly controlled. Regarding risk factors, almost 64% showed hypercholesterolemia; 18% were smokers; 35% of males and 28% of females showed hyperglicemia and 63% of the latter had a waist line > 88 cm; 32% used to consume alcohol (46% males and 15% females); 26% had a metabolic syndrome; 13% was affected by vascular brain injuries, 30% by peripheral artheriopaty, 35% had heart diseases, 10% was nephropatic and 13% diabetic. CONCLUSIONS By this project we evidenced that, with simple devices and low costs, it is possible to make people understand the importance of self-measurement for a more practical management of the illness, for the follow-up of the BP values and to verify the efficiency of the treatment. A more active and direct role of hypertensive patients in their own medical care could reasonably bring a reduction of expenses in long-term management of the disease, a reduction of inappropriate shifts of therapy and, as seen, an increased reliability of the self-measured pressure values.
Collapse
|
41
|
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2011; 26:520-6. [PMID: 21904377 DOI: 10.1038/leu.2011.240] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Rescue chemotherapy or autologous stem cell transplantation (autoSCT) gives disappointing results in relapsed peripheral T-cell lymphomas (PTCLs). We have retrospectively evaluated the long-term outcome of 52 patients receiving allogeneic SCT for relapsed disease. Histologies were PTCL-not-otherwise specified (n=23), anaplastic large-cell lymphoma (n=11), angioimmunoblastic T-cell lymphomas (n=9) and rare subtypes (n=9). Patients were allografted from related siblings (n=33, 64%) or alternative donors (n=13 (25%) from unrelated and 6 (11%) from haploidentical family donors), following reduced-intensity conditioning (RIC) regimens including thiotepa, fludarabine and cyclophosphamide. Most of the patients had chemosensitive disease (n=39, 75%) and 27 (52%) failed a previous autoSCT. At a median follow-up of 67 months, 27 of 52 patients were found to be alive (52%) and 25 (48%) were dead (n=19 disease progression, n=6 non-relapse mortality (NRM)). The cumulative incidence (CI) of NRM was 12% at 5 years. Extensive chronic graft-versus-host disease increased the risk of NRM (33% versus 8%, P=0.04). The CI of relapse was 49% at 5 years, influenced by disease status at the time of allografting (P=0.0009) and treatment lines (P=0.007). Five-year overall survival and progression-free survival (PFS) were 50% (95% CI, 36 - 63%) and 40% (95% CI, 27 - 53%), respectively. The current PFS was 44% (95% CI, 30-57%). In all, 8 out of 12 patients (66%) who received donor-lymphocytes infusions for disease progression had a response. At multivariable analysis, refractory disease and age over 45 years were independent adverse prognostic factors. RIC allogeneic SCT is an effective salvage treatment with a better outcome for younger patients with chemosensitive disease.
Collapse
Affiliation(s)
- A Dodero
- Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
San-Miguel JF, Lonial S, Hungria V, Moreau P, Einsele H, Lee JH, Yoon S, Corradini P, Jedrzejczak WW, Tan DC, Yong K, Guenther A, Wroclawska-Swacha MM, Weber HJ, Bourquelot PM, Richardson PGG. PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps227] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Guidetti A, Carlo-Stella C, Viviani S, Devizzi L, Locatelli S, Matteucci P, Marchianò A, Lanocita R, Magni M, Dodero A, Tarella C, Di Nicola MA, Corradini P, Gianni AM. Safety and activity of the multikinase inhibitor sorafenib in heavily pretreated patients with refractory/relapsed malignant lymphomas: Final results of a phase II study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. Eur J Cancer 2011; 47:814-8. [PMID: 21334196 DOI: 10.1016/j.ejca.2010.12.026] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 12/23/2010] [Accepted: 12/23/2010] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Lenalidomide is a thalidomide analogue, designed to have improved efficacy and tolerability over the parent drug. The aim of this retrospective analysis is to evaluate the impact of thalidomide therapy on lenalidomide response and outcome in relapse or refractory multiple myeloma patients. PATIENTS AND METHODS A total of 106 relapsed or refractory multiple myeloma patients received lenalidomide 25mg plus dexamethasone as salvage therapy; 80 patients progressed on thalidomide treatment (thalidomide-resistant) and 26 patients discontinued thalidomide in at least partial remission (thalidomide-sensitive). Median time from diagnosis to lenalidomide treatment was 57 months. Median prior lines of therapies were 3, range 1-6. 62% of patients were previously treated with autologous stem cell transplantation, and 71% with bortezomib-based regimens. RESULTS In the thalidomide-resistant and -sensitive groups, the at least partial response rates were 56.2% and 61.5% (P = .45), including at least VGPR rates of 16.2% and 11.5%; the median progression free survival was 10 and 12 months (P=.12) and the median overall survival was 17 and 18.5 months (P = .50), respectively. CONCLUSION Lenalidomide may be equally effective in heavily pre-treated multiple myeloma patients who are thalidomide-resistant or thalidomide-sensitive to a previous therapy.
Collapse
Affiliation(s)
- T Guglielmelli
- Department of Clinical and Biological Sciences, University of Turin and San Luigi Hospital, Orbassano, Turin, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011; 22:1614-1621. [PMID: 21245159 DOI: 10.1093/annonc/mdq703] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Outcomes of Ewing tumor (ET) patients treated with allogeneic stem cell transplantation (allo-SCT) were compared regarding the use of reduced-intensity conditioning (RIC) and high-intensity conditioning (HIC) regimens as well as human leukocyte antigen (HLA)-matched and HLA-mismatched grafts. PATIENTS AND METHODS We retrospectively analyzed data of 87 ET patients from the European Group for Blood and Marrow Transplantation, Pediatric Registry for Stem Cell Transplantations, Asia Pacific Blood and Marrow Transplantation and MetaEICESS registries treated with allo-SCT. Fifty patients received RIC (group A) and 37 patients received HIC (group B). Twenty-four patients received HLA-mismatched grafts and 63 received HLA-matched grafts. RESULTS Median overall survival was 7.9 months [±1.24, 95% confidence interval (CI) 5.44-10.31] for group A and 4.4 months (±1.06, 95% CI 2.29-6.43) for group B patients (P = 1.3). Death of complications (DOC) occurred in 4 of 50 (0.08) and death of disease (DOD) in 33 of 50 (0.66) group A and in 16 of 37 (0.43) and 17 of 37 (0.46) group B patients, respectively. DOC incidence was decreased (P < 0.01) and DOD/relapse increased (P < 0.01) in group A compared with group B. HLA mismatch was not generally associated with graft-versus-Ewing tumor effect (GvETE). CONCLUSIONS There was no improvement of survival with RIC compared with HIC due to increased DOD/relapse incidence after RIC despite less DOC incidence. This implicates general absence of a clinically relevant GvETE with current protocols.
Collapse
Affiliation(s)
- U Thiel
- Department of Pediatrics and Wilhelm Sander Sarcoma Unit MRI, Pediatric Oncology Center, Technische Universität München
| | - A Wawer
- Department of Pediatrics and Wilhelm Sander Sarcoma Unit MRI, Pediatric Oncology Center, Technische Universität München
| | - P Wolf
- Institute for Medical Statistics and Epidemiology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
| | - M Badoglio
- EBMT Data & Study Office, Hopital Saint-Antoine, Assistance Publique des Hôpitaux de Paris and UPMC Univ Paris 06, Paris, France
| | - A Santucci
- Section of Pediatric Hematology & Oncology, University of Perugia, Perugia, Italy
| | - T Klingebiel
- Children's Hospital III, Department of Pediatrics, Johann Wolfgang Goethe University, Frankfurt
| | - O Basu
- Children's Hospital III, Department of Pediatrics, Johann Wolfgang Goethe University, Frankfurt
| | - A Borkhardt
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany
| | - H-J Laws
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany
| | - Y Kodera
- Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University, Aichi; APBMT Data Center, Nagoya University School of Medicine, Nagoya, Japan
| | - A Yoshimi
- APBMT Data Center, Nagoya University School of Medicine, Nagoya, Japan
| | - C Peters
- Department of Pediatrics, St. Anna Kinderspital, Vienna, Austria
| | - R Ladenstein
- Department of Pediatrics, St. Anna Kinderspital, Vienna, Austria
| | - A Pession
- Department of Scienze Pediatriche Mediche e Chirurgiche, Ospedale S Orsola Malpighi, Bologna, Italy
| | - A Prete
- Department of Scienze Pediatriche Mediche e Chirurgiche, Ospedale S Orsola Malpighi, Bologna, Italy
| | - E-C Urban
- Department of Pediatrics, Medical University of Graz, Graz, Austria
| | - W Schwinger
- Department of Pediatrics, Medical University of Graz, Graz, Austria
| | - P Bordigoni
- Service de Transplantation Medullaire, CHU de Nancy Brabois, Vandoeuvre-les-Nancy, France
| | - A Salmon
- Service de Transplantation Medullaire, CHU de Nancy Brabois, Vandoeuvre-les-Nancy, France
| | - M A Diaz
- Department of Pediatrics, Division of Pediatric Hematology-Oncology and Hematopoietic Stem Cell Transplantation and Cell Therapy Unit, Hospital Infantil Universitario Niño Jesus, Madrid, Spain
| | - B Afanasyev
- St. Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children`s Institute, Department of Hematology and Transplantology, St. Petersburg, Russia
| | - I Lisukov
- St. Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children`s Institute, Department of Hematology and Transplantology, St. Petersburg, Russia
| | - E Morozova
- St. Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children`s Institute, Department of Hematology and Transplantology, St. Petersburg, Russia
| | - A Toren
- Pediatric Hemato-Oncology Unit, Sheba Medical Center (affiliated to the Sackler Faculty of Medicine), Tel Hashomer, Israel
| | - B Bielorai
- Pediatric Hemato-Oncology Unit, Sheba Medical Center (affiliated to the Sackler Faculty of Medicine), Tel Hashomer, Israel
| | - J Korsakas
- Department of Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania
| | - F Fagioli
- Stem Cell Transplantation and Cellular Therapy Unit, Pediatric Onco-Hematology Division, "Regina Margherita" Children's Hospital, Turin
| | - D Caselli
- Department of Oncoematologia Pediatrica, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy
| | - G Ehninger
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden
| | - B Gruhn
- Department of Pediatrics, University of Jena, Jena
| | - U Dirksen
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - F Abdel-Rahman
- The Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan
| | - M Aglietta
- Department of Istituto per la Ricerca e la Cura del Cancro, Turin, Italy
| | - E Mastrodicasa
- Section of Pediatric Hematology & Oncology, University of Perugia, Perugia, Italy
| | - M Torrent
- Hospital de la Santa Creu i Sant Pau, Department of Pediatrics, Barcelona, Spain
| | - P Corradini
- Department of Hematology - Bone Marrow Transplantation Unit, Istituto Nazionale dei Tumori, University of Milano, Milan, Italy
| | - F Demeocq
- Centre Hospitalier et Universitaire de Clermont-Ferrand, Service de Pédiatrie B et Unité Bioclinique de Thérapie Cellulaire, Clermont-Ferrand, France
| | - G Dini
- Department of UO Ematologia ed Oncologia Pediatrica, Istituto G Gaslini, Genova, Italy
| | - P Dreger
- Department of Internal Medicine V, University of Heidelberg, Heidelberg
| | - M Eyrich
- Children's Hospital, Department of Paediatric Stem Cell Transplantation, University of Würzburg, Würzburg, Germany
| | - J Gozdzik
- Transplantation Centre, University Children's Hospital, Cracow, Poland
| | - F Guilhot
- Department of Hematology, University Hospital, Poitiers, France
| | - E Holler
- Department of Hematology and Oncology, University of Regensburg, Regensburg
| | - E Koscielniak
- Department of Pediatrics 5 (Oncology, Hematology, Immunology), Olga Hospital, Klinikum Stuttgart, Stuttgart, Germany
| | - C Messina
- Hemo/Oncology, Department of Pediatrics, Hospital-University of Padova, Padova, Italy
| | - D Nachbaur
- University Hospital of Innsbruck, Internal Medicine V, Department of Hematology and Oncology, Innsbruck, Austria
| | - R Sabbatini
- Department of Oncology, Haematology, and Respiratory Diseases, Policlinico di Modena, Modena
| | - E Oldani
- Department of U.S.C. Ematologia, Ospedali Riuniti, Bergamo, Italy
| | - H Ottinger
- Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
| | - H Ozsahin
- Paediatric Oncology Unit, University of Geneva Children's Hospital, Geneva, Switzerland
| | - R Schots
- Division of Clinical Hematology and BMT Unit, University Hospital Brussels, Brussels, Belgium
| | - S Siena
- Department of S. C. Divisione Oncologia Falck and S. C. Divisione Anatomia Patologica, Ospedale Niguarda Ca' Granda, Milan, Italy
| | - J Stein
- Bone marrow Transplant Unit, Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - S Sufliarska
- Bone Marrow Transplantation Unit, Department of Pediatrics, Comenius University Medical School, Bratislava, Slovak Republic
| | - A Unal
- Institutions Erciyes Medical School, Department of Hematology and Oncology, Kapadokya BMT Center, Kayseri, Turkey
| | - M Ussowicz
- Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | - P Schneider
- Department of Pediatric Hematology and Oncology, Hôpital Charles Nicolle, Rouen, France
| | - W Woessmann
- Department of Pediatric Hematology and Oncology, University Hospital, Giessen, Germany
| | - H Jürgens
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - M Bregni
- Unit of Medical Oncology, Ospedale San Giuseppe, Milan, Italy
| | - S Burdach
- Department of Pediatrics and Wilhelm Sander Sarcoma Unit MRI, Pediatric Oncology Center, Technische Universität München.
| | | | | | | |
Collapse
|
46
|
Benedetti E, Corradini P, Goodman M, Pedone C. Flexibility of supposed "rigid" molecules: substituted 2,5-piperazinediones (diketopiperazines). Proc Natl Acad Sci U S A 2010; 62:650-2. [PMID: 16591734 PMCID: PMC223646 DOI: 10.1073/pnas.62.3.650] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The relevant results of accurate X-ray analyses of both the trans-and the L-cis-3,6-dimethyl-2,5-piperazinediones (diketopiperazines) are reported. We note that a large variability of conformations for the ring system can be accomplished by coupling small bond-angle deformations with large variations of the internal rotation angles. The experimental molecular models are discussed in terms of these changes and in terms of nonbonded intramolecular interactions.
Collapse
Affiliation(s)
- E Benedetti
- POLYMER RESEARCH INSTITUTE, POLYTECHNIC INSTITUTE OF BROOKLYN, NEW YORK
| | | | | | | |
Collapse
|
47
|
Carlo-Stella C, Guidetti A, Viviani S, Bonfante V, Marchiano A, Gatti B, D'Urzo C, Di Nicola MA, Corradini P, Gianni AM. Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Antinori S, Corbellino M, Necchi A, Corradini P, Vismara C, Montefusco V, Gianni A. Immune reconstitution inflammatory syndrome associated withAspergillus terreuspulmonary infection in an autologous stem cell transplant recipient. Transpl Infect Dis 2010; 12:64-8. [DOI: 10.1111/j.1399-3062.2009.00460.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Vitali G, Corradini P, Ciceri F, Peccatori J. 7129 Long-term follow-up of metastatic renal cancer patients undergoing HLA-identical reduced-intensity allografting. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71462-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
50
|
Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, Corradini P, Ciceri F, Peccatori J. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7037 Background: Stem cell transplantation from a HLA-compatible sibling donor is an adoptive immunotherapy for cytokine-refractory, metastatic clear-cell renal cell cancer (RCC). However, the recent introduction of targeted therapy compounds has reduced the interest in this therapeutic strategy. We have reanalyzed our series with the aim to assess long-term benefit from allografting. Methods: Twenty-five RCC patients (Table) received a reduced-intensity allograft from an HLA-identical sibling donor after a thiotepa, fludarabine, and cyclophosphamide conditioning regimen, and a cyclosporine-based GVHD prophylaxis. Allogeneic peripheral blood hematopoietic cells were collected by apheresis after filgrastim treatment of the donor. Results: Best response to allograft was evaluable in 24 patients: 1 complete remission, 4 partial remissions, 12 minor response or stable disease, 7 progressive disease. Six patients died because of transplant related mortality (TRM) at day +12, +71, +86, +151, +259, +478. Cause of death was infection in four cases, GVHD in one case, and acute renal failure in one case. Fourteen patients died for progressive disease at median 415 (36–958) days from transplant. One-year survival was 48%, and 5-yr survival was 20%. At a median observation time of 65 months, 5 patients are alive, one in CR, one in PR, and three with stable disease. At multivariate analysis, CRP value before transplant, number of CD34+ infused cells and disease status at +90 significantly correlated with survival. Survival of patients at favourable/intermediate-risk according to the MSKCC score that underwent allografting was better in comparison to the survival predicted by historical controls. Conclusions: Transplantation is able to induce long-term disease control in a fraction (20%) of relapsed RCC patients. Identifying patients who could benefit from allografting, and incorporating molecularly targeted drugs in the transplant regimen, could further decrease progression and prolong overall survival. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Bregni
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - M. Bernardi
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - P. Servida
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - A. Pescarollo
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - R. Crocchiolo
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - E. Treppiedi
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - P. Corradini
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - F. Ciceri
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - J. Peccatori
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| |
Collapse
|